Subscription to raise £1.65 million and Sharing Agreements

14th December 2021

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a conditional subscription to raise £1.65 million with Lanstead Capital Investors L.P.

Download News

Back to all News